MAP2K1 and hepatocellular carcinoma: In our study, we treated ITLN1-overexpressed HCC cells with 50 μM MEK1/2 inhibitor, PD98059, to investigate the impact of the ERK1/2 signaling on the growth inhibition and regulation of cell cycle-related proteins induced by ITLN1 in HCC cells.